A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Dose Finding Study To Investigate the Safety and Tolerability of YM150 in Subjects With Non-Valvular Atrial Fibrillation and to Compare the Safety and Tolerability With Warfarin
A Phase 2, Double-Blind, Double-Dummy, Randomized, Parallel Group Dose Finding Study To Investigate the Safety and Tolerability of YM150 in Subjects With Non-Valvular Atrial Fibrillation and to Compare the Safety and Tolerability With Warfarin
The purpose of this study is to investigate the optimal daily dose and dose regimen of YM150 in subjects with non-valvular atrial fibrillation (NVAF), primarily based on safety and tolerability data.
Inclusion Criteria:
Exclusion Criteria:
Victoria, 3181, Australia
Besenov, 25630, Czechia
Havirov-mesto, 73601, Czechia
Hyderabaad, 500036, India
Higashiibaraki-gun, 311 3193, Japan
Meguro-ku, 153-8515, Japan
Shimajiri-gun, 901-0496, Japan
Shinjyuku-ku, 162-8543, Japan
Selangor Darul Ehsan, 47500, Malaysia
AD Delft, 2625, Netherlands
AE Roosendaal, 4708, Netherlands
BC Amsterdam, 1091, Netherlands